SCCA | Strategic Alliance Partners

October 21, 2021

David Zhen, MD, discusses the need for novel therapies in poorly differentiated small-cell-type neuroendocrine tumors.

October 12, 2021

With new therapeutic options, such as enfortumab vedotin-ejfv and, available to treat patients with locally advanced or metastatic urothelial cancer who require second- or third-line therapy, early detection of disease progression is critical.

October 11, 2021

Efforts to move beyond chemotherapy alone for patients with advanced urothelial cancer, shift effective treatments into the curative setting in renal cell carcinoma, and effectively escalate treatment for patients with high-risk and high-volume prostate cancer have been successfully met.

September 30, 2021

September 27, 2021

William P. Harris, MD, discusses remaining questions regarding treatment sequencing after atezolizumab and bevacizumab in hepatocellular carcinoma.

September 24, 2021

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

September 21, 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.

September 13, 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the importance of patient selection for cytoreductive surgery in colorectal cancer with peritoneal involvement.

September 09, 2021

Stacey A. Cohen, MD, discusses the importance of patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

September 07, 2021

David Zhen, MD, discusses advancements in the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

September 06, 2021

E. Gabriela Chiorean, MD, discusses some of the recent developments in pancreatic cancer, HCC, and NETs, as well as multidisciplinary approaches for treating these patients.

September 03, 2021

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the incidence and prognosis of peritoneal carcinomatosis in colorectal cancer.

September 03, 2021

William P. Harris, MD, discusses updated data from the phase 3 IMbrave150 study in hepatocellular carcinoma.

September 02, 2021

Stacey A. Cohen, MD, discusses tailoring treatment approaches to individual subtypes in colorectal cancer.

September 02, 2021

E. Gabriela Chiorean, MD, discusses the role of molecular testing in pancreatic cancer.

August 10, 2021

William P. Harris, MD, discusses the adoption of immunotherapy in advanced hepatocellular carcinoma.

August 04, 2021

Stacey A. Cohen, MD, discusses the standardization of triplet-based chemotherapy regimens in colorectal cancer.

August 02, 2021

Stacey A. Cohen, MD, discusses the clinical implications of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

July 21, 2021

July 06, 2021

Hannah M. Linden, MD, discusses the potential for enobosarm in patients with metastatic breast cancer, data from a phase 2 trial examining its use, and next steps for the agent in the paradigm.